NCT07703020Enrolling by invitation
Prevalence and Determinants of Obesity in PKU Patients
Phenylketonuria Associated With Obesity: a Cross-sectional Pilot Study on Prevalence and Possible Contributive Factors
Source: ClinicalTrials.gov · Last updated 14 Jul 2026
Brief summary (registry, in English)
This observational cross-sectional multicenter study aims to assess the prevalence of overweight and obesity in adult patients with phenylketonuria (PKU) and to identify associated risk factors. Adult PKU patients followed in metabolic centers in Switzerland and Austria will be evaluated using clinical data, laboratory parameters, and standardized questionnaires addressing diet, physical activity, and psychological factors. The study seeks to better understand contributors to weight gain in this population to inform preventive strategies.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 24 Mar 2026
- Start date
- 1 Mar 2026
- Primary completion date
- 1 Feb 2028
- Lead sponsor
- Christel Tran
- Diseases
- Obesity
- NCT number
- NCT07703020
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Mar 2026 to the primary completion date, 1 Feb 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Pregnant or lactating women.
- Inability to follow the study procedures (e.g., due to language barriers).
- Eligible participants who refuse to be informed of any important health concern discovered during the study.
- Investigators, their family members, employees, or anyone with a personal link to the investigator other than a doctor-patient relationship.
Who the study is looking for
- Confirmed diagnosis of phenylketonuria (PKU) by biochemical and/or molecular testing.
- Age ≥ 18 years.
- Ability to provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lausanne University Hospital Coordinator of this site? Confirm its status | Lausanne | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.